These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 2798993)

  • 1. [Ca 125 in the diagnosis and follow-up of ovarian neoplasia].
    Baviera G; Antico F; Bagnato A; Purello D'Ambrosio F
    Riv Eur Sci Med Farmacol; 1989 Feb; 11(1):59-64. PubMed ID: 2798993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The value of CA 125 determination in the serum of patients with ovarian cancer].
    Bartel U; Johannsen B; Elling D
    Zentralbl Gynakol; 1989; 111(5):301-9. PubMed ID: 2728673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical use of CA-125 in gynecology. Preliminary experience].
    Mayerson D; Badía J; Wild R; Barrena N; Johnson MC; Foradori A
    Rev Chil Obstet Ginecol; 1989; 54(5):301-6. PubMed ID: 2490419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Results of CA-125 tumor marker determination in patients with ovarian carcinoma].
    Miladinović D; Paunović R; Paunković N
    Jugosl Ginekol Perinatol; 1989; 29(3-4):83-5. PubMed ID: 2601371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Ovarian carcinoma antigen (CA 125) and ovarian cancer (clinical follow-up and prognostic studies)].
    Göcze P; Vahrson H
    Orv Hetil; 1993 Apr; 134(17):915-8. PubMed ID: 8479736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Ca 125 as tumor marker in ovarian carcinoma.
    Krebs HB; Goplerud DR; Kilpatrick SJ; Myers MB; Hunt A
    Obstet Gynecol; 1986 Apr; 67(4):473-7. PubMed ID: 3008052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The serum concentrations of TAG-72 antigen measured with CA 72-4 IRMA in patients with ovarian carcinoma. Preliminary data.
    Gadducci A; Ferdeghini M; Ceccarini T; Prontera C; Facchini V; Bianchi R; Fioretti P
    J Nucl Med Allied Sci; 1989; 33(1):32-6. PubMed ID: 2746365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The decline of CA 125 level after surgery reflects the size of residual ovarian cancer.
    Brand E; Lidor Y
    Obstet Gynecol; 1993 Jan; 81(1):29-32. PubMed ID: 8416457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
    Oehler MK; Sütterlin M; Caffier H
    Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The CA-125 tumor marker in epithelial ovarian cancers of stage I].
    Nagele F; Vavra N; Kurz C; Sevelda P
    Wien Klin Wochenschr; 1993; 105(20):585-8. PubMed ID: 8259686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value of biological markers in the diagnosis and monitoring of cystadenocarcinoma].
    Bidart JM; Bellet D
    Rev Prat; 1989 Nov; 39(26):2317-20. PubMed ID: 2595221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
    Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
    Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of tumour marker measurements upon management of patients with carcinoma of the ovary.
    Rustin GJ
    Dis Markers; 1991; 9(3-4):153-8. PubMed ID: 1813207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathology of the ovary.
    McGowan L
    Curr Opin Obstet Gynecol; 1991 Aug; 3(4):580-6. PubMed ID: 1878514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Application of monoclonal antibody OC 125 in gynecological oncology].
    Wu AR; Wang EY; Wang XX; Jia XH; Li L
    Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):132-6. PubMed ID: 3208653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnosis of the recurrence of epithelial ovarian cancer with the tumor marker CA 125].
    Sevelda P; Wagner G
    Wien Klin Wochenschr; 1987 Nov; 99(21):768-70. PubMed ID: 3480655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical usefulness of serum and immunohistochemical markers in patients with stage Ia and Ic ovarian cancer.
    Muramatsu T; Mukai M; Sato S; Tajima T; Nagase E; Ikeda M; Goya K; Shida M; Hirasawa T; Murakami M; Shinozuka T
    Oncol Rep; 2005 Oct; 14(4):861-5. PubMed ID: 16142343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyst fluid CA 125 levels in ovarian epithelial neoplasms.
    Menczer J; Ben-Baruch G; Moran O; Lipitz S
    Obstet Gynecol; 1993 Jan; 81(1):25-8. PubMed ID: 8416456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the CA 125 assay in the management of ovarian cancer.
    Niloff JM
    Oncology (Williston Park); 1988 Aug; 2(8):67-76. PubMed ID: 3275060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.